rAAV production cost analysis: Indication-specific cost per dose and reduction strategies
The first comprehensive, platform-resolved cost analysis of rAAV production across three industrially relevant suspension platforms is presented, suggesting the potential for improved supply feasibility, even for high-dose neuromuscular indications, under the modeled assumptions of productivity improvement and process...